Humanized anti-IL-1β antibodies
US7541033B2 · kind B2 · utility
5Cited by
6References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2004 |
| Grant date | Jun 2, 2009 |
| Priority date | — |
| Expiry date | Feb 5, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.